Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study

Table 3

The endocrine and metabolic assessment of patients before (week 0) and after (week 24) the treatment with Tracnil™.

Group	LH (mIU/ml)	FSH (mIU/ml)	LH/FSH ratio
Before	12.51 ± 2.29	13.61 ± 4.84	1.692 ± 0.223
After	17.91 ± 3.17	22.13 ± 5.73	1.393 ± 0.217

Data shown as mean ± SEM for a sample size of N = 32 patients. Student’s t-test indicated no difference () between the levels before and after treatment.